Log in to save to my catalogue

Scelte terapeutiche e trattamento con sorafenib nell’epatocarcinoma: analisi finale dello studio GID...

Scelte terapeutiche e trattamento con sorafenib nell’epatocarcinoma: analisi finale dello studio GID...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3174419651

Scelte terapeutiche e trattamento con sorafenib nell’epatocarcinoma: analisi finale dello studio GIDEON in Italia

Publication information

Publisher

Rome: Il Pensiero Scientifico Editore

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Introduction. Sorafenib, an oral multikinase inhibitor, is the only targeted agent approved for the treatment of patients with hepatocellular carcinoma (HCC) after demonstration to increase overall survival compared to placebo in two randomized phase III study. GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with s...

Alternative Titles

Full title

Scelte terapeutiche e trattamento con sorafenib nell’epatocarcinoma: analisi finale dello studio GIDEON in Italia

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_3174419651

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3174419651

Other Identifiers

ISSN

0034-1193

E-ISSN

2038-1840

DOI

10.1701/1868.20406

How to access this item